(Q36734084)

16 August 2017

1 reference

title

Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies (English)

1 reference

16 August 2017

0 references

Adam Szczuciński

1

1 reference

16 August 2017

Jacek Losy

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 March 2007

1 reference

Acta Neurologica Scandinavica

16 August 2017

published in

1 reference

16 August 2017

volume

115

1 reference

16 August 2017

issue

3

1 reference

16 August 2017

page(s)

137-146

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

16 August 2017

1 reference

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The pathology of multiple sclerosis: a historical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Mechanisms of demyelination and tissue destruction in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Multiple sclerosis: novel perspectives on newly forming lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Increased serum levels of soluble PECAM-1 in multiple sclerosis patients with brain gadolinium-enhancing lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines and matrix metalloproteinase-9 in leukocyte recruitment to the central nervous system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Cytokines in multiple sclerosis: from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The CD4-Th1 model for multiple sclerosis: a critical [correction of crucial] re-appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

CNS chemokines, cytokines, and dendritic cells in autoimmune demyelination

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines and leukocyte traffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines--chemotactic cytokines that mediate inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The expression and function of chemokines involved in CNS inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The many roles of chemokines and chemokine receptors in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines in the brain: neuroimmunology and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines: a new classification system and their role in immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

International Union of Pharmacology. XXX. Update on chemokine receptor nomenclature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Eotaxin-3/CCL26 is a natural antagonist for CC chemokine receptors 1 and 5. A human chemokine with a regulatory role.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The ligands of CXC chemokine receptor 3, I-TAC, Mig, and IP10, are natural antagonists for CCR3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Absence of monocyte chemoattractant protein 1 in mice leads to decreased local macrophage recruitment and antigen-specific T helper cell type 1 immune response in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Treatment of experimental autoimmune encephalomyelitis with the chemokine receptor antagonist Met-RANTES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

CXCL10 (IFN-gamma-inducible protein-10) control of encephalitogenic CD4+ T cell accumulation in the central nervous system during experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Neutralization of IFN-inducible protein 10/CXCL10 exacerbates experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

IFN-inducible protein 10/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Distinct roles for IP-10/CXCL10 in three animal models, Theiler's virus infection, EAE, and MHV infection, for multiple sclerosis: implication of differing roles for IP-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Critical roles of CXC chemokine ligand 16/scavenger receptor that binds phosphatidylserine and oxidized lipoprotein in the pathogenesis of both acute and adoptive transfer experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

CCL2 and CCL5 mediate leukocyte adhesion in experimental autoimmune encephalomyelitis--an intravital microscopy study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Investigating chemokines and chemokine receptors in patients with multiple sclerosis: opportunities and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Expression of CCR7 in multiple sclerosis: implications for CNS immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines CXCL10 and CCL2: differential involvement in intrathecal inflammation in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Longitudinal study of chemokine receptor expression on peripheral lymphocytes in multiple sclerosis: CXCR3 upregulation is associated with relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokine receptors associated with immunity within and outside the central nervous system in early relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Targeting the chemokine receptor CXCR3 and its ligand CXCL10 in the central nervous system: potential therapy for inflammatory demyelinating disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The CCR5 deletion mutation fails to protect against multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Influence of CCR5 delta32 polymorphism on multiple sclerosis susceptibility and disease course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

RANTES: a genetic risk marker for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

CXC chemokine receptors on human oligodendrocytes: implications for multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Differential intracellular expression of CCR5 and chemokines in multiple sclerosis subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Steroid therapy altered serum levels of CCL2 and CCL5 chemokines in multiple sclerosis patients during relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Effect of high-dose methylprednisolone treatment on CCR5 expression on blood cells in MS exacerbation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Increased CXCL8 (IL-8) expression in Multiple Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Multi-faceted strategies to combat disease by interference with the chemokine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Drug discovery and chemokine receptor antagonists: eppur si muove!

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

New directions in MS therapeutics: vehicles of hope

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Development and evaluation of pharmacological agents targeting chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

The clinical potential of chemokine receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Onset of multiple sclerosis associated with anti-TNF therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Therapeutic targeting of alpha 4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

Expression of chemokine receptors in the different clinical forms of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0404.2006.00749.X

10.1111/J.1600-0404.2006.00749.X

21 January 2018

Identifiers

DOI

1 reference

16 August 2017

1 reference